CD44 is a cell surface receptor for hyaluronate, a component of the extracellular matrix (ECM). Although CD44 has been implicated in tumor invasion and metastasis, the molecular mechanisms remain to be elucidated. Here we ®nd that CD44 expressed in cancer cells is cleaved at the membrane-proximal region of the ectodomain and the membrane-bound cleavage product can be detected using an antibody against the cytoplasmic domain of CD44. Furthermore, we report that CD44 cleavage is mediated by a membraneassociated metalloprotease expressed in cancer cells. A tissue inhibitor of metalloproteases-1 (TIMP-1), as well as metalloprotease inhibitors, inhibit CD44 cleavage in the cell-free assay. Contrary, serine protease inhibitors enhance CD44 cleavage, and the enhancement can be prevented by pretreatment with a metalloprotease inhibitor. Thus, CD44 cleavage is regulated by an intricate balance between some proteases and their inhibitors. Interestingly, treatment with the metalloprotease blocker 1,10-phenanthroline, which strongly prevent the CD44 cleavage, suppressed RERF-LC-OK lung cancer cell migration on a hyaluronate substrate, but not on several other substrates. These results suggest that CD44 cleavage plays a critical role in an ecient celldetachment from a hyaluronate substrate during the cell migration and consequently promotes CD44-mediated cancer cell migration. Our present data indicate that CD44, not only ECM per se, is one of the targets of pericellular proteolysis involved in tumor invasion and metastasis.
Introduction
Metastatic spread and aggressive invasion are de®ning features of cancer and continue to be the greatest barrier of cancer cure. Cancer cell migration plays a central role in these processes. It is therefore of primary importance to achieve a better understanding of the molecular mechanisms involved in cancer cell migration.
Cell surface adhesion molecules are crucial for the migratory process, as they couple interactions with the extracellular matrix (ECM) to the cytoskeletal apparatus inside the cell (Lauenburger and Horwitz, 1996) . CD44 is the principal cell surface receptor for hyaluronic acid (HA) (Aruo et al., 1990) and is closely associated with the cytoskeleton (Isacke, 1994; Tsukita et al., 1994) , that is implicated in a wide variety of biological processes, including lymphocyte homing and activation (Goldstein et al., 1989; Arch et al., 1992; Toyama-Sorimachi et al., 1997) , cell adhesion (Culty et al., 1990) , cell migration (Thomas et al., 1992) and metastatic spread of cancer cells (GuÈ nthert et al., 1991) .
Most CD44 functions are shown to be associated with its ability of interaction with HA, and the ability can be regulated by several mechanisms. The phosphorylation of the cytoplasmic domain of CD44 in leukocytes has been reported to be requisite for CD44-mediated HA binding (Pure et al., 1995) . The ectodomain of CD44 can be modi®ed by alternative splicing, whereby various combinations of 10 variant exons can be inserted into a single membrane-proximal site, generating numerous CD44 splice variants (CD44v) Screaton et al., 1992) . Expression of certain CD44 splice variants are found in several human cancers (Matsumura and Tarin, 1992; Tanabe et al., 1993a; Okamoto et al., 1998; . The alternative splicing represents one of the mechanisms for regulation of hyaluronate recognition by CD44 Bartolazzi et al., 1995; Bennett et al., 1995; Sleeman et al., 1996) . Moreover, the ectodomain of CD44 is subject to posttranslational glycosylation, which both negatively and positively in¯uences its ability to bind hyaluronate (Katoh et al., 1995; Lesley et al., 1995; Bartolazzi et al., 1996) . These regulation systems involved in CD44-HA interactions have been considered to give CD44 the wide diversity of its biological functions, including tumor growth, invasion and metastasis (GuÈ nthert et al., 1991; Sy et al., 1991; Bartolazzi et al., 1994 Bartolazzi et al., , 1995 Takahashi et al., 1995; Sheng et al., 1997) . Although CD44 is known to take part in cancer cell migration through recognition of HA (Thomas et al., 1992; Okada et al., 1996; Goebeler et al., 1996) , the ®ndings raise the question as to how the CD44 function is regulated during the migration process. Cancer cell migration requires a dynamic interaction between the cell and ECM, including not only rapid rates of adhesive formation but also dissolution to allow a cell to progress over substratums (Albelda, 1993; Lauffen-burger and Horwitz, 1996) . Molecular mechanisms underlying such highly dynamic regulation of interaction between CD44 and ECM remain to be elucidated.
In this report, we have raised a polyclonal antibody (anti-CD44cyto pAb) directed against the CD44 cytoplasmic domain. By employing this antibody, we have found that CD44 expressed in cancer cells is constitutively cleaved at membrane-proximal region. Previous works have shown that CD44 can be enzymatically released from the leukocyte surface upon appropriate stimulation, such as phorbolester or cross-linking by speci®c antibodies (Bazil and Strominger, 1994) . Moreover, a soluble form of CD44 was reported to be released into the culture supernatants of several cancer cell lines Goebeler et al., 1996; GuÈ nthert et al., 1996) . We now extend these observations by demonstrating that a membrane-associated metalloprotease expressed in cancer cells cleaves the ectodomain of CD44 in the cancer cells at a membrane-proximal site. We further show several intriguing properties of the metalloprotease responsible for CD44 cleavage. Finally, we present that CD44-mediated cancer cell migration is suppressed in the presence of metalloprotease inhibitor which prevent CD44 cleavage. These results demonstrate that CD44 cleavage contributes to the regulation of CD44-HA interactions required for the migration process, and consequently promotes CD44-mediated cancer cell migration.
Results

Detection of CD44 protein by anti-CD44 cytoplasmic domain antibody
We raised a polyclonal antiserum (anti-CD44cyto pAb) against a synthetic peptide corresponding to the cytoplasmic domain of CD44. The ability of antiCD44cyto pAb to recognize the CD44 protein was initially evaluated by immunocytochemical analysis of CD44-expressing cultured cells. Immuno¯uorescence staining using an anti-CD44ecto mAb, which recognizes an ectodomain epitope common to all CD44 isoforms, demonstrated that CD44 was distributed over the entire cell surface of U251MG human glioma cells and was concentrated in sites of cell-cell contact and in ®lopodia (Figure 1a ). Anti-CD44cyto pAb also displayed an identical immunoreactive pattern in U251MG, whereas preimmune serum did not exhibit immunoreactivity under the same conditions (Figure 1b and c).
To further examine the speci®c recognition of CD44 by anti-CD44cyto pAb, Western blot analysis was performed on CD44 stable transfectants. cDNA encoding human CD44s isoform lacking all variant exons or CD44v8-10 isoform containing variant exons 8, 9 and 10 was cloned into a pRc/CMV vector, and these constructs were transfected into VMRC-LCD human lung cancer cells, which does not express endogenous CD44 protein. The pRc/CMV containing only the drug resistance gene without inserts was used as a control vector. G418-resistant stable transfectants were analyzed by Western blotting using antiCD44ecto mAb or anti-CD44cyto pAb. Both antibodies recognized 85 and 130 kDa bands in lysates of CD44s (VMRC-LCD/CD44s) and CD44v8-10 (VMRC-LCD/CD44v8-10) transfectants, respectively ( Figure 2a ). Molecular weights of each band were identical to those of the intact membrane-spanning CD44s or CD44v8-10, as demonstrated previously in many cell types Bartolazzi et al., 1994 . In contrast, speci®c bands were not detected in either the parental VMRC-LCD (data not shown) or the control vector transfected cells (VMRC-LCD/C). These data indicate that anti-CD44cyto pAb is useful for speci®c detection of CD44 protein.
Identi®cation of a 25 kD species as a CD44 cleavage product in various cancer cell lines
It evoked our great interest that anti-CD44cyto pAb recognized a 25 kD band in lysates of CD44 transfectants, in addition to recognizing the intact membrane-spanning form of CD44 (Figure 2a ). Since the band was not found in the parental and control transfected cells, the 25 kD species was likely to be related to ectopically expressed CD44. The 25 kD species, as well as the full-length CD44, were detected in the membrane fraction washed with 1 M NaCl (data not shown), indicating that the species are anchored to the membrane by a transmembrane domain. Although the 25 kD species could not be recognized by antiCD44ecto mAb, the molecular weight of the species was greater than the predicted size of CD44 cytoplasmic and transmembrane domains. Therefore, the species may have contained a part of the CD44 ectodomain in addition to the cytoplasmic and Figure 1 Immunocytochemical staining of CD44 in U251MG cells. U251MG cells were stained with anti-CD44ecto mAb (a), antiCD44cyto pAb (b) and preimmune serum (c) followed by FITC-conjugated secondary antibody (green¯uorescence). Nuclei were stained by propidium iodide (red¯uorescence). Cells were photographed at the same magni®cation (4006) by a standard uorescence microscope CD44 cleavage by membrane-associated metalloproteases I Okamoto et al transmembrane domains. Taken together, we can reason that the 25 kD species detected with antiCD44cyto pAb is a proteolytic derivative yielded as a result of cleavage of the CD44 ectodomain ( Figure 2b ). To determine whether endogenous CD44 is also cleaved to generate the 25 kD species, we performed Western blot analysis in various cancer cell lines. In the lysates from all cell lines examined, the intact CD44s protein of 85 kD was detected with both antiCD44ecto mAb and anti-CD44cyto pAb (Figure 3a) . The 25 kD species detected with anti-CD44cyto pAb, but not anti-CD44ecto mAb, was exhibited in U251MG, T98G, 105MG, RERF-LC-OK and PANC-1, whereas the species was hardly detectable in SF126, RERF-LC-MA and SUIT-2. Since cleavage of the CD44 ectodomain is believed to generate soluble CD44 in addition to the 25 kD cleavage product, we examined the levels of soluble CD44 in the supernatants of these cancer cell lines. One hundred thousand cells were cultured in serum-free medium for 24 h, and the culture supernatants were analysed for soluble CD44 by an ELISA system. Cell lines which displayed the 25 kD species in Western blot analysis released much larger amounts of soluble CD44 into the supernatant than the other cell lines, in which the 25 kD species were hardly detectable ( Figure 3b ). These results indicate that endogenous CD44 expressed on the surface of cancer cells can be spontaneously cleaved at the ectodomain, thereby yielding the 25 kD cell-bound fragment and soluble CD44 ectodomain, which are detectable in cancer cells that have high CD44 cleavage activity.
The eect of metalloprotease inhibitors on CD44 cleavage
To determine what types of proteases are responsible for spontaneous CD44 cleavage at the surface of cancer cells, we studied the eects of inhibitors of various known classes of proteases on the cleavage activity. U251MG cells, which have high CD44 cleavage activity (Figure 3 ), were treated with various protease inhibitors and each cell lysate was analysed by Western blot using anti-CD44cyto pAb. As demonstrated in Figure 4a , treatment with 1,10-phenanthroline and EDTA, agents which chelate cations associated with metalloprotease, caused the disappearance of the 25 kD cleavage product. 1,7-phenanthroline, an inactive analogue of 1,10-phenanthroline, did not aect the amounts of the cleavage product. Furthermore, the eects of hydroxamic acid based peptides, BB2516 (marimastat) and CGS27023A (Talbot and Brown, 1996) , which are speci®c metalloprotease inhibitors were also examined. Treatment with both these peptide inhibitors prevented the production of the 25 kD species in a dose-dependent manner (Figure 4a and b) . In addition, ELISA analysis of culture supernatants revealed that treatment with metalloprotease inhibitors blocked the release of soluble CD44 into the supernatant (Figure 4c ). Identical results were also obtained from other cell lines with high CD44 cleavage activity, including T98G, 105MG, RERF-LC-OK and PANC-1 (data not shown). These results clearly indicate that a member of the metalloprotease family is responsible for CD44 cleavage in cancer cells.
CD44 cleavage in cancer cells by a membrane-associated metalloprotease
We examined whether the metalloprotease responsible for CD44 cleavage is a soluble secreted enzyme or a membrane-bound enzyme. We ®rst incubated for 4 h SF126 cells (3610 5 cells), which consistently have very low CD44 cleavage activity, in the culture supernatants of U251MG cells (1.5610 6 cells) which have high CD44 cleavage activity. The 25 kD CD44 cleavage product was hardly detectable in cell lysates extracted from the treated SF126 cells by Western blot analysis using anti-CD44cyto pAb ( Figure 5a ). Moreover,¯ow cytometry analysis using anti-CD44ecto mAb showed no reduction in the cell-surface expression of CD44 on the SF126 cells after the treatment (Figure 5b ). These results suggest that the metalloprotease involved in CD44 cleavage is not be a soluble secreted enzyme.
To explore whether the protease has a membraneassociated activity, we utilized cell-free CD44 cleavage assays. Crude membranes were isolated from U251MG or RERF-LC-OK. The membranes were incubated at 378C for 120 min and then analysed by Western blot using anti-CD44cyto pAb. After incubation, the 25 kD cleavage product markedly increased compared to the preincubated control sample, and the full-length 85 kD CD44 showed a concomitant quantitative decrease in intensity ( Figure 5c , lanes 1 and 2). The cell-free CD44 cleavage was also observed when the membrane fractions were washed with buer containing 1 M NaCl ( Figure 5c , lane 3). These results indicate that the in vitro CD44 cleavage can be induced under the conditions we utilized and the responsible protease is an integral membrane protein. Furthermore, the in vitro CD44 cleavage reaction was blocked by BB2516 and CGS27023A (Figure 5d ), but not by serine, cysteine and aspartate protease inhibitors (data not shown). These results suggest that the putative protease involved in CD44 cleavage in cancer cells is a member and CGS27023A as follows BB2516 10 nM, 100 nM, 1 mM, 10 mM and 100 mM (lanes 2, 3, 4, 5, 6, respectively) or CGS27023A 100 nM, 1 mM, 10 mM and 100 mM (lanes 7, 8, 9, 10, respectively) and then analysed by Western blotting using anti-CD44cyto pAb. (c) U251MG cells were incubated for 24 h at 378C in the absence (control) or presence of 1,10-phenanthroline (5 mM), EDTA (5 mM), BB2516 (100 mM) and CGS27023A (100 mM) and the cell-free supernatants were analysed for soluble CD44 using an ELISA system. Mean values and standard deviation of triplicate samples for one experiment are shown and are representative of three similar experiments CD44 cleavage by membrane-associated metalloproteases I Okamoto et al of the membrane-bound metalloprotease family. Additionally, a tissue inhibitor of metalloproteases-1 (TIMP-1), a natural inhibitor of all known matrix metalloproteases, inhibited the CD44 cleavage in the cell-free system, as well as BB2516 and CGS27023A, while TIMP-2 did not aect the cleavage (Figure 5d , lanes 6 and 7). These ®ndings imply that the metalloprotease responsible for CD44 cleavage belongs to a matrix metalloprotease family.
The eect of serine, cysteine and aspartate protease inhibitors on CD44 cleavage
For further characterization of the CD44 cleavage metalloprotease, the eects of inhibitors for serine (AEBSF, DCI, TLCK, TPCK or FOY-305), cysteine (E-64) and aspartate (pepstatin A) type proteases on CD44 cleavage were also examined. U251MG cells were treated with these protease inhibitors and each The cell-surface expression of CD44 on SE126 cells cultured with¯esh mediun (upper) or the cell-free supernatants from U251MG cells (lower) was determined by¯ow cytometric analysis using anti-CD44ecto mAb. The x-axis shows logarithm of¯uorescence and the yaxis shows cell number. (c) Analysis of the CD44 cleavage metalloprotease activity in a cell-free assay. RERF-LC-OK membrane fractions were washed extensively with either icecold Tris-HCl (30 mM, pH 7.2) (lanes 1, 2) or the same buer containing 1 M NaCl (lane 3). The washed membrane fractions reconstituted in ice-cold Tris-HCl (30 mM, pH 7.2) were either immediately mixed with SDS sample buer (lane 1) or incubated at 378C for 2 h (lanes 2, 3), and then analysed by Western blotting using anti-CD44cyto pAb. (d) The CD44 cleavage metalloprotease is a member of the membrane-bound metalloprotease family. RERF-LC-OK membrane fractions (20 ml aliquots) suspended in ice-cold Tris-HCl (30 mM, pH 7.2) were either immediately mixed with SDS sample buer (no incubation, lane 1) or incubated at 378C for 2 h with no agents (no treatment, lane 2), DMSO as a buer control (lane 3), 100 mM BB2516 (lane 4), 100 mM CGS27023A (lane 5), 10 mg/ml TIMP-1 (lane 6) and 10 mg/ml TIMP-2 (lane 7). Each aliquot was subjected to Western blot analysis using anti-CD44cyto pAb cell lysate was analysed by Western blot using antiCD44cyto pAb. Treatment with serine protease inhibitors reduced amounts of 85 kD intact CD44, with a corresponding increase in 25 kD cleavage products (Figure 6a ). On the other hand, cysteine or asparatic protease inhibitors caused little change in amounts of 85 kD CD44 and cleavage products (Figure 6a) . Moreover, the release of soluble CD44 was also strongly accelerated by treatment with the serine protease inhibitors, but not with cysteine or asparatic proteinase inhibitors (Figure 6b ). Similar results were also obtained when RERF-LC-OK cells were used (data not shown). These results indicate that the serine protease inhibitors, in contrast to metalloprotease inhibitors, enhance CD44 cleavage in cancer cells. Flow cytometry analysis with anti-CD44ecto mAb showed that the CD44 cleavage enhanced by these serine protease inhibitors, but not by cysteine or asparatic proteinase inhibitors, resulted in rapid downregulation of cell surface CD44 expression with a reduction detectable 30 min after the treatment ( Figure  7 ). We next investigated whether the enhancement of CD44 cleavage by the serine protease inhibitors is mediated by metalloproteases. As demonstrated in Figure 7 , pretreatment with BB2516 markedly blocked CD44 cleavage enhanced by the serine protease inhibitors. The same eect was also con®rmed with CGS27023A (data not shown). These observations indicate that metalloprotease-mediated CD44 cleavage in cancer cells are rapidly stimulated by the serine protease inhibitors. One explanation of these results is that unknown serine proteases expressed in cancer cells have a negative regulatory eect on CD44 cleavage activity via metalloproteases.
Deletion within the putative cleavage region of CD44 ectodomain did not inhibit CD44 cleavage CD44 splice variants are generated by insertion of variant exons at a single site in the membrane proximal of the ectodomain. The insertion site has been located at 46 amino acids distant from the membrane (Figure 8a ). Interestingly, Western blot analysis using anti-CD44cyto pAb demonstrated that both CD44s (VMRC-LCD/CD44s) and CD44v8-10 (VMRC-LCD/CD44v8-10) transfected cells generated the same size (25 kD) of CD44 cleavage products ( Figure 2a ). These ®ndings mapped the putative cleavage sites of CD44 to a short region of the ectodomain, between the proximal end of the variant exons insertion region and the beginning of the transmembrane domain (Figure 8a ). To determine whether the short region of the ectodomain is required for CD44 cleavage, CD44s and CD44s deleted 44 consecutive amino acids within the putative cleavagè stalk' region were epitope-tagged with Myc at the carboxyl terminus, and these constructs (CD44s-Myc, CD44s Dstalk-Myc) were transiently expressed in COS-7 cells. Western blot analysis using anti-Myc mAb showed that both the 85 kD intact CD44 and the cleavage products were detected in lysates of CD44s-Myc transfected COS-7 cells, but not in lysates of mock transfectants (Figure 8b , lanes 1 and 2). Treatment with BB2516 blocked generation of the cleavage product (Figure 8b, lane 3) . These results strongly indicate that COS-7 cells can cleave the ectodomain of ectopically expressed CD44 in a manner similar to that observed in cancer cells. Unexpectedly, lysates of CD44s Dstalk-Myc transfected COS-7 cells yielded both the full-length form of the mutant CD44 and the cleavage product detected by anti-Myc mAb (Figure 8b, lane 4) . Moreover, appearance of the cleavage product derived from CD44s Dstalk-Myc transfectants was also blocked by BB2516 (Figure 8b , lane 5). These data indicate that deletion of the membrane-proximal putative CD44 cleavage region does not prevent CD44 cleavage signi®cantly. These ®ndings suggest that proteolytic cleavage of CD44 may not have required strict sequence speci®city, as previously reported in several cell surface molecules that are known to undergo membrane-proximal proteolysis (Hooper et al., 1997) . Possible interpretation of these results is that the proteolytic cleavage depends on a higher order structure of CD44. CD44 undergoes disul®de bridges from U251MG treated with various protease inhibitors. U251MG cells were incubated at 378C for the indicated time in either the absence (control) or presence of various inhibitors at concentrations described above, and then the cell-free supernatants were analysed for soluble CD44 using an ELISA system. The results shown are representative of three independent experiments CD44 cleavage by membrane-associated metalloproteases I Okamoto et al Figure 7 Eect of serine, cystein, aspartate protease inhibitors on cell-surface expression of CD44. U251MG were incubated at 378C for 30 min either in buer control (red curve) or various inhibitors, as indicated, at concentrations described above (green curve), and in a series of experiments, U251MG were treated with 100 mM BB2516 1 h prior to and during incubation with indicated inhibitors (blue curve). Then the cells were stained for CD44 expression with anti-CD44ecto mAb and analysed on a FACScan¯ow cytometer. The x-axis shows logarithm of¯uorescence and the y-axis shows cell number Dstalk-Myc, as indicated. On day 3 after transfection, cells were cultured overnight in the presence of either DMSO as a buer control (lanes 2, 4) or 100 mM BB2516 (lanes 3, 5), and then analysed by Western blotting using anti-Myc mAb (9E10). The bands (*) at 50 ± 60 kD below the CD44s-Myc or CD44s Dstalk-Myc full length represent incompletely glycosylated CD44 protein and is heavily glycosylated, which must in¯uence topology of the protein. To examine whether the protein structure imposed by the disul®de bridges and glycosylation contributes to CD44 cleavage, we treated U251MG and RERF-LC-OK with dithiothreitol (DTT) (1 mM) or with tunicamycin (1 mg/ml), and then analysed the eect on CD44 cleavage by Western blot using anti-CD44cyto pAb. The drug concentrations used have shown no cytotoxicity in a period of at least 24 h. Disruption of disul®de bridges by DTT and inhibition of N-linked glycosylation by tunicamycin dramatically reduced the amounts of 25 kD CD44 cleavage product, indicating prevention of CD44 cleavage (Figure 9 ). These data suggest that changes in disul®de bridges and glycosylation status of CD44 may be crucial for CD44 to be recognized by the CD44 cleavage metalloprotease.
Role of CD44 cleavage in cancer cell migration on hyaluronic acid (HA)
CD44 has been reported to be a matrix adhesion receptor for HA (Aruo et al., 1990) and to be associated with cell migration (Thomas et al., 1992; Okada et al., 1996; Goebeler et al., 1996) . To explore the biological signi®cance of CD44 cleavage, we next sought to examine the role of CD44 cleavage in cancer cell migration on HA. We performed Boyden chambertype migration assays using 8 mm porosity polycarbonate ®lters coated on the bottom side with ECM substrates. In a series of pilot experiments, we found that RERF-LC-OK cells, which have high CD44 cleavage activity, highly migrated through HA-coated membranes but not chondroitin-6-sulfate-coated membranes used as a control. Furthermore, anti-CD44ecto mAb signi®cantly inhibited the migration of RERF-LC-OK cells on HA compared with an isotypematched control monoclonal antibody. In contrast, anti-CD44ecto mAb did not reduce the migration on other ECM sustrates including laminin, type-I-collagen, ®brinogen and ®bronectin (Figure 10a ). These evidence strongly support the idea that RERF-LC-OK cell migration on HA is CD44-dependent. Using RERF-LC-OK cells, we examined the eect of metalloprotease inhibitor 1,10-phenanthroline on the cell migration. Strikingly, the presence of 1,10-phenanthroline (40 mM, 80 mM) exhibited a dosedependent reduction in the RERF-LC-OK cell migration on HA, but no reduction on laminin, type-Icollagen, ®brinogen and ®bronectin, suggesting that the eect of the inhibitor is speci®c for CD44-mediated migration (Figure 10b ). These results indicate that a metalloproteolytic activity, including the CD44 cleavage metalloprotease is crucially involved in CD44-mediated migration on HA, and suggest that CD44 cleavage signi®cantly contributes to the migration process of some cancer cells. 
Discussion
In this study, we have demonstrated that a membraneassociated metalloprotease, which is expressed in cancer cells, is involved in the proteolytic cleavage of cell-surface CD44. Previous reports indicated that serine protease inhibitors, TLCK and 3,4-DCI, as well as metalloprotease inhibitors inhibited CD44 cleavage from the cell surface of phorbolesterstimulated leukocytes (Bazil and Strominger, 1994) . However our present results, using several serine protease inhibitors, have clearly showed that these serine protease inhibitors rapidly enhance CD44 cleavage in cancer cells and the enhancement is blocked by pretreatment with metalloprotease inhibitors. Thus, it is likely that the CD44 cleavage mechanisms in cancer cells are partly dierent from those in stimulated leukocytes. Our ®ndings indicated that CD44 cleavage at the cancer cell surface is potentially regulated by an intricate balance between serine protease and metalloprotease activities. Serine proteases and metalloproteases are known to play an important role in tumor invasion and metastasis (Chambers and Matrisian, 1997; Werb, 1997) . At invasive protrusion of cancer cells, these proteases have been suggested to degrade the extracellular matrix (ECM), and subsequently facilitate invasion of cancer cells into the surrounding normal tissue. The ECM is a continuum with the cancer cell surface, which has diverse receptors for the ECM. Expression of these cell surface receptors, including adhesion molecules, has also been reported to be associated with either increases or decreases in the ability of cancer cells to adhere to ECM (Albelda, 1993) . Thus, ECM proteolysis, adhesion and deadhesion are all brought to bear on migrating and invading cancer cells. Our present data give the evidence that CD44, not only ECM per se, is one of the targets of pericellular proteolysis involved in this series of events. The metalloprotease responsible for CD44 cleavage is located and acts on the cancer cell surface and these properties can provide a highly ecient proteolysis system to be assembled in the pericellular region of a migrating cell.
Notably, in our cell-free assay, CD44 cleavage was inhibited by TIMP-1, in addition to metalloprotease inhibitors, but not by TIMP-2. This observation is reminiscent of the membrane-type matrix metalloproteases (MT-MMPs) as a candidate for the CD44 cleavage metalloprotease. Recently, four MT-MMPs (MT1, 2, 3 and 4-MMP) have been identi®ed. The proMMP-2 activation by MT1-MMP has been found to be a key role for tumor cell invasion and metastasis . MT2-MMP and MT3-MMP have also been shown to activate proMMP-2 (Will and Hinzmann, 1995; Takino et al., 1995) . It can be speculated that one of these known MT-MMPs cleave CD44 as another substrate in the process of invasion and metastasis. However, based on the previous reports that the proteolytic activities of MT1, 2 and 3-MMP can be more eciently inhibited by TIMP-2 than TIMP-1, these MT-MMPs are unlikely to have CD44 cleavage activity. MT4-MMP is structurally dierent from these three enzymes because of its low amino acid sequence homology, and its activity and the nature of its molecular targets remain to be characterized (Puente et al., 1996) . The CD44 cleavage metalloprotease may be a novel member of the MT-MMP family or be an entirely new class of membranetype metalloprotease.
CD44, as the principal cell surface receptor for hyaluronic acid (Aruo et al., 1990) , has been shown to play a critical role in regulation of tumor cell migration (Thomas et al., 1992; Okada et al., 1996; Goebeler et al., 1996) . The cytoplasmic domain of CD44 interacts with the ezrin/radixin/moesin (ERM) family which are thought to function as cross-linking protein between plasma membranes and actin ®laments (Tsukita et al., 1994) . The CD44/ERM complex formation has been reported to be dynamically regulated by the small GTP binding protein Rho which is a key signaling molecule associated with cytoskeletal rearrangements (Hirao et al., 1996; Takahashi et al., 1997; Amano et al., 1997; Matsui et al., 1998) . Thus, it is speculated that cytoskeletalmediated intracellular dynamics is involved in CD44-mediated cell migration. However, since cell migration is likely to be regulated by a coordination between the cytoskeletal rearrangements and the dynamic regulation of cell-ECM substrate adhesion (Lauenburger and Horwitz, 1996) , the mechanisms controlling the state of adhesive contacts with the substrate are also important aspects to be considered. The cell adhesion to ECM during cell migration may not be so tight as to prevent movement nor too weak to provide traction (Palecek et al., 1997) . In addition, migration requires mechanisms that regulate the release of adhesions to allow the cells to detach from the substrate (Lauenburger and Horwitz, 1996) . Cellular migration speed thus depends upon the rate of cycling between attachment to and detachment from a substrate. The release of adhesions at the rear of migrating cells likely results from several mechanisms, including`ripping' of b1 integrins, cytoskeletal contraction and signal transduction pathways involving regulatory components such as Rho, calcineurin, and tyrosine kinase (Lauenburger and Horwitz, 1996) . Recent work has revealed that L-selectin cleavage from leukocytes can occur during the rolling process and regulate the rolling velocity (Walcheck et al., 1996) .
Taking the diverse dynamics of a migrating cell into account, high-anity binding of CD44 to HA, which mediates cell adhesion to ECM, is unlikely to be the only function of CD44 during cell migration. In our experiments, CD44-mediated migration on HA was highly sensitive to the metalloprotease blocker 1,10-phenanthroline, which strongly inhibited CD44 cleavage. The ®nding suggests that CD44 cleavage is the primary requirement for promotion of cell motility on HA. We cannot completely exclude the possibility that the inhibitor may have unknown actions, in addition to inhibiting CD44 cleavage, that may aect cell migration on HA. However, it is reasonable to hypothesize that CD44 cleavage plays a role in cell detachment from CD44-HA adhesive sites during the course of cell migration and acceleration of cellular migration by providing osetting changes in adhesiveness. This speculation is consistent with the previously reported observation that melanoma cells release CD44 ectodomain at the detachment zone during migration in 3-dimensional collagen lattices (Friedl et al., 1997) .
Determination of the actual cleavage site of CD44 and production of a cleavage-resistant CD44 mutant will allow us to show directly the mechanism and functional role of CD44 cleavage on cancer cells. However, we have demonstrated that total deletion of the membrane-proximal putative cleavage region is not sucient to prevent the CD44 cleavage at the surface of transfected COS-7 cells. Such apparently relaxed sequence speci®city at cleavage sites of membraneproximal proteolysis has been described previously for several cell surface molecules such as L-selectin, bamyloid precursor protein and angiotensin-converting enzyme (Hooper et al., 1997) . These ®ndings suggest that cleavage of these molecules is likely to be governed by several factors, including not only the amino-acid sequence but physical length or conformation of the cleavage region. In the present study, we have suggested that CD44 cleavage is more severely restricted to tertiary structure of CD44 altered by disul®de bridges or N-linked glycosylation rather than the sequence at the cleavage region. However, we can not rule out the possibility that DTT or tunicamycin treatment alter the high order structure of the CD44 cleavage metalloprotease and result in the prevention of CD44 cleavage.
We have reported herein that CD44 expressed in cancer cells is proteolyticaly cleaved by membraneassociated metalloprotease and that this CD44 regulatory mechanism is involved in tumor cell migration, which is central to pathogenesis in tumor metastasis. Identi®cation of the CD44 cleavage metalloprotease, and understanding how CD44-mediated adhesion and CD44 cleavage are integrated will provide exciting avenues for investigation of the biological role of CD44 in tumor progression, and development of new therapeutical approaches for cancer.
Materials and methods
Tumor cell lines and transfection
The human glioblastoma cell lines U251MG, SF126, T98G and 105MG, and the human pancreatic cancer cell line PANC-1 were obtained from the American Type Culture Collection (Rockville, MD, USA). The human lung cancer cell lines VMRC-LCD, RERF-LC-OK and RERF-LC-MA were purchased from the Japanese Cancer Research Resources Bank (JCRB, Tokyo, Japan). The human pancreatic cancer cell line SUIT-2 was generously provided by Dr T Iwamura (Miyazaki Medical College, Miyazaki, Japan) (Iwamura et al., 1997) . All cells were grown in Dulbecco's modi®ed Eagle's medium with Ham's F-12 nutrient mixture (DMEM/F-12) (Life Technologies, Inc. (GIBCO ± BRL), Grand Island, NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) (Bio-Whittaker, Walkersville, MD, USA) at 378C in an atmosphere containing 5% CO 2 .
The human CD44s and CD44v8-10 expression plasmids were kindly provided by Dr K Tanabe (Massachusetts General Hospital, Boston, MA, USA). They were generated by subcloning the CD44s cDNA or CD44v8-10 cDNA into the mammalian expression vector pRC/CMV (Invitrogen, San Diego, CA, USA) (Takahashi et al., 1995) . These expression plasmids were transfected into VMRC-LCD cells by the liposome-mediated gene transfer method (Felgner et al., 1987) . Brie¯y, 2610 5 VMRC-LCD cells were plated in a 6-cm dish 24 h before transfection. Five mg of puri®ed CD44s or CD44v8-10 cloned pRC/CMV or pRC/CMV only (no cDNA insert) was added to VMRC-LCD cells after preincubation for 20 min with 5 mg of lipofectamine reagent and 3 ml of serum free OPTI-MEM (Life Technologies, Inc.). Drug selection, in 500 mg/ml Geneticin (Sigma Chemical Co., St Louis, MO, USA), was begun 72 h after transfection. After drug selection, colonies were harvested with cloning cylinders and expanded to cell lines.
Antibodies and reagents
The monoclonal antibody F10-44-2 (Novocastra Laboratories Ltd., Newcastle, UK) and BU52 (Ancell Co., Bayport, MN, USA) are directed against the ectodomain epitope common to all CD44 isoforms. An antibody against the cytoplasmic domain of CD44, anti-CD44cyto pAb, was raised by subcutaneous immunization of rabbits with a synthetic peptide (DQFMTADETRNLQNVDM-KIGV) which was coupled to KLH. MAB065, an anti-rat b-tubulin mouse monoclonal antibody that reacts with btubulin from all species (plant to human), was purchased from Chemicon International Inc. Immuno¯uorescence procedure and confocal laser scanning microscopic analysis Cells were seeded on Lab-TekII Chamber Slide (Nalge Nunc Int., Naperville, IL, USA) and incubated for 24 h at 378C, then washed two times with PBS and ®xed in 4% paraformaldehyde for 10 min followed by 0.2% Triton X-100 for 5 min. After being washed with PBS, the cells were incubated with diluted F10-44-2 (1 : 100), anti-CD44cyto pAb (1 : 100) or preimmune serum (control) (1 : 100) in PBS containing 0.3% bovine serum albumin (BSA) for 90 min at room temperature. After being washed with PBS, the cells were incubated with diluted FITC-conjugated secondary antibody (1 : 100) (Biosource, Camarillo, CA, USA) for 60 min. For the ®nal 5 min, propidium iodide (Sigma) was added to make a ®nal concentration of 1 mg/ml for nuclear staining. After being washed with PBS, samples were mounted in 50% glycerol and visualized with a confocal microscope (TCS 4D, Leica, Nussloch, Germany) equipped with an argon gas laser and appropriate ®lter sets to allow the simultaneous recording of¯uorescein. Fluorescence micrographs were recorded using PL APO 406objec-tives and were sampled at 102461024 pixels and 8-bit resolution per color.
Western blot analysis
For the Western blot analysis, the cultured cells were mechanically scraped and the cell pellets after centrifugation at 5000 r.p.m. for 3 min at 48C, were immediately 
Enzyme-linked immunosorbent assay (ELISA)
Supernatants of treated cells were ®ltered using a 0.22 mm millipore ®lter (Millipore, Bedford, MA, USA) before analysis. Soluble CD44 in the culture supernatant was quanti®ed using a soluble CD44s ELISA kit (Bender MedSystem, Vienna, Austria) according to the manufacturer's instructions.
Preparation of membrane fractions
The cultured cells were mechanically scraped and suspended in ®ve volumes of ice-cold hypotonic lysis buer (20 mM HEPES pH 7.5, 10 mM KOAc, 1.5 mM MgOAc), supplemented with 20 mM EDTA. After sitting on ice for 15 min, the cells were disrupted using Douncehomogenizer (Cosmo Bio Co., Ltd.). The nuclei were removed by centrifugation at 2000 g for 5 min at 48C, and the supernatant was centrifuged again at 10 000 g for 1 h at 48C. The sedimented membranes were suspended in ice-cold Tris×HCl (30 mM, pH 7.2) containing various components to be tested. The reaction mixture (20 ml) was transferred to 378C and incubated for 120 min. The reaction was stopped by the addition of an equal quantity of SDS sample buer and incubated at 1008C for 5 min. Then, aliquots of reaction mixtures were subjected to Western blot analysis using anti-CD44cyto pAb.
Membrane washing
Crude membranes were added to 10 volumes of ice-cold 1 M NaCl in 30 mM Tris×HCl (pH 7.2) and kept 15 min on ice. Membranes were collected by centrifugation at 10 000 g for 15 min at 48C. Washed membranes were reconstituted in ice-cold Tris×HCl (30 mM, pH 7.2) and assayed as described above.
Flow cytometry analysis
Cells were detached from plates with 5 mM EDTA in serum-free medium, washed with PBS and incubated with diluted F10-44-2 (1 : 50) in PBS containing 1% FBS and 0.3% NaN 3 at 48C for 30 min. After being washed with PBS, cells were incubated with diluted FITC-conjugated goat anti-mouse IgG (1 : 100) (Biosource) at 48C for 30 min. Cells were washed in PBS, resuspended in PBS, and immediately analysed by¯ow cytometry on a FACScan (Becton Dickinson Immunocytometry Sys., Mountain View, CA, USA).
Construction of CD44s-Myc and CD44s Dstalk-Myc expression plasmids
The full-length CD44s cDNA were ampli®ed by PCR from the cDNA of normal peripheral blood lymphocytes by the following primers: CD44s-Sense (5'-CCGTTGAATTCG--CAAG-3') containing an EcoRI site (underlined) and CD44s-Antisense (5'-GTGTAGGGTACCCACCCCAAT-CTTCAT-3') containing a KpnI site (underlined). The PCR fragments were digested with EcoRI and KpnI and then ligated into pBJ-Myc expression plasmids which was kindly provided by Dr A Kikuchi. CD44s Dstalk cDNA that has deletion of nucleotides 1245 ± 1373 (Tanabe et al., 1993b) , resulting in removal of 44 amino acids in the membrane-proximal stalk region of CD44s, was generated by PCR using full length CD44s cDNA as a template with the two primers described above and additional twò`i nner'' primers. These inner primers, CD44s del-Sense (5'-CAAATTAGATCTTGGCTGATCATCTTGGCATCC-CTC-3') and CD44s del-Antisense (5'-GTCTTGAGATCT-GGTAGCAGGGATTCTGTCTGTGCT) containing a BglII site (underlined), were respectively complementary to the downstream and upstream sequences immediatelȳ anking the deletion site. The PCR fragments ampli®ed by CD44s-Sense and CD44s del-Antisense were digested with EcoRI and BglII and the fragments ampli®ed by CD44s-Antisense and CD44s del-Sense were digested with BglII and KpnI. Then, the resultant two PCR products were ligated together into pBJ-Myc expression plasmids. The inserted cDNA sequences were all veri®ed by DNA sequence analysis. Transfection of COS-7 cells with either CD44s-Myc or CD44s Dstalk-Myc expression plasmids was performed by the liposome-mediated gene transfer method.
Migration assay
Cell migration was assayed using 48-well modi®ed Boyden chambers (Neuro Probe Inc., Bethesda, MD, USA) with polycarbonate Nucleopore ®lters of 8 mm pore size (Nucleopore Corp., Pleasonton, CA, USA). The undersides of ®lters were precoated with 1 mg/ml hyaluronic acid (Sigma), 1 mg/ml chondroitin-6-sulfate (Sigma), 10 mg/ml laminin (Sigma), 10 mg/ml type I collagen (Seikagaku Co., Tokyo, Japan), 200 mg/ml ®brinogen (Sigma) or 10 mg/ml ®bronectin (Sigma). Prior to the assays, the ®lters were washed in PBS and air dried. The lower compartments of the modi®ed Boyden chamber were ®lled with serum-free DMEM/F-12 containing ethanol (control) or 1,10-phenanthroline (40 mM or 80 mM) and the ECM-coated ®lters were placed into the chamber with the coated membrane side facing the lower compartments. RERF-LC-OK cells in a logarithmic phase of growth were detached by brief exposure to trypsin-EDTA and resuspended at 10 6 cells/ ml in serum-free DMEM/F-12 containing ethanol (control) or 1,10-phenanthroline (40 mM or 80 mM). These cells were added to the upper compartments at 5 610 4 cells/ compartment. In experiments investigating the role of CD44 in cell migration, the cells were incubated with 20 mg/ml BU52 or isotype-matched control monoclonal antibody (Ancell Co.) diluted in serum-free DMEM/F-12 20 min prior to and during the migration assay. Chambers were subsequently incubated at 378C in a 5% CO 2 atmosphere for 6 h. After removal of ®lters, cells on the non-coated upper membrane side were gently wiped o. Filters were ®xed in methanol, stained with Giemsa solution and mounted on glass slides. Cells that had migrated to the coated side of the ®lters were counted in a blinded fashion using light microscopy under high power ®eld (HPF; 4006). The number of cells in ®ve de®ned HPFs was counted and the average was determined. Each assay was performed in triplicate.
